Two patients with prolactinomas were resistant to both depot-bromocriptine, and large doses of oral dopamine agonists. Initiating side-effects (nausea, vomiting, symptomatic postural hypotension) were seen in five patients in the first 24 h post-injection, but were minimal or absent thereafter. ...
Trials with oral aripiprazole have shown that, compared with some other atypical antipsychotics, aripiprazole is associated with fewer metabolic disturbances and has a favourable cardiovascular tolerability profile. Recently, an intramuscular long-acting injectable (LAI) depot formulation of aripiprazole (...
“Platform of the World Health Organisation”. For search terms see webappendix 1. The last search was performed in April 2016. We also researched the medical reviews that pharmaceutical companies submitted to the FDA and we inquired with the providers ofpaliperidone palmitateand risperidone depot (...
If patients received both depot and oral formulations, doses were summed (e.g., for patients receiving 400 mg depot formulation and an oral supplement of 5 mg of aripiprazole, the total dose would be (400 mg/30 day) + 5 mg = 18.33 mg/day). 2.3. Statistical analysis Clinical variables...
Aripiprazole lauroxil is the prodrug of aripiprazole and is available as a long-acting intramuscular injection (1064 mg, 441 mg, 662 mg, or 882 mg) that can be administered every 4 to 6 weeks and requires a three-week oral medication overlap. ...
EPA-1546 - Paliperidone palmitate in non-acute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral aripiprazole To explore tolerability, safety and treatment response of flexibly dosed once-monthly paliperidone palmitate (PP) in adult nonacute patients with schizophrenia pre...
Consider dose reduction to 300 mg/month if adverse reaction occurs Abilify Asimtufii (IM every 2 months) Never taken aripiprazole Establish tolerability with oral aripiprazole before initiating 960 mg IM q2Months May take up to 2 weeks to fully assess tolerability Continue oral aripiprazole (10-...
Concurrent with the first injection of LAI aripiprazole, oral aripiprazole was continued for 2 weeks. Subjects who remained stable consistently for at least 3 months on depot aripiprazole were randomized into the study in a 2:1 active to placebo ratio, with a total of 403 patients reaching ...
Doses were adjusted to patient's weight and clinical needs, but averaged 100 mg/month. Patients randomized to AM received intradeltoid or intragluteal injections of 400 mg/month Abilify Maintena (aripiprazole once monthly, Otsuka, Tokyo, Japan) at baseline and 10–20 mg/day oral aripiprazole ...
The study consisted of two phases: a screening phase (up to 28 days), which included stabilization on oral aripiprazole; and a randomization/treatment assignment phase (24 weeks), in which patients received one of three different dose levels of aripiprazole once-monthly (200 mg, 300 mg or ...